Research programme: sterile injectable products - Eton Pharmaceuticals

Drug Profile

Research programme: sterile injectable products - Eton Pharmaceuticals

Alternative Names: ACTH analogue - Eton Pharma; Corticotropin - Eton Pharma; Injectable corticotropin - Eton; Injectable pentoxifylline - Eton; Pentoxifylline - Eton Pharma; Synthetic corticotropin - Eton Pharma

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Imprimis Pharmaceuticals
  • Developer Eton Pharmaceuticals
  • Class Corticosteroids; Hypothalamic hormones; Small molecules; Xanthines
  • Mechanism of Action Corticotropin receptor agonists; Cytokine inhibitors; Immunosuppressants; Phosphoric diester hydrolase inhibitors; Steroid receptor agonists; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ankylosing spondylitis; Arthritis; Infantile spasms; Inflammation; Multiple sclerosis; Peyronie's disease

Most Recent Events

  • 20 Jun 2017 Preclinical development is ongoing for Peyronie's disease in USA
  • 20 Jun 2017 Injectable formulations of synthetic corticotropin and pentoxifylline licensed to Eton Pharmaceuticals worldwide
  • 20 Jun 2017 Eton Pharmaceuticals has pending patents for a gelatin-free and preservative free 39 amino acid peptide synthetic corticotropin, an adrenocorticotropic hormone (ACTH) analogue and an injectable formulation of pentoxifylline for the treatment of Peyronie's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top